Sarra El-Abed
Overview
Explore the profile of Sarra El-Abed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, et al.
JAMA
. 2025 Jan;
PMID: 39883436
Importance: Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic...
2.
Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, et al.
Nat Commun
. 2024 Nov;
15(1):10402.
PMID: 39613746
In HER2-positive breast cancer, clinical outcome and sensitivity to HER2-targeted therapies are influenced by both tumor and microenvironment features. However, we are currently unable to depict the molecular heterogeneity of...
3.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, et al.
JAMA Oncol
. 2024 Mar;
10(5):603-611.
PMID: 38546612
Importance: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer (EBC). Objective: To define the quantitative...
4.
Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U, et al.
Breast Cancer Res Treat
. 2023 Nov;
203(3):497-509.
PMID: 37938495
Purpose: To assess whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early breast cancer (EBC). Methods: ALTTO (NCT00490139) patients were categorized by ESA use during adjuvant...
5.
Rediti M, Fernandez-Martinez A, Venet D, Rothe F, Hoadley K, Parker J, et al.
Nat Commun
. 2023 Nov;
14(1):7053.
PMID: 37923752
The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate...
6.
Partridge A, Niman S, Ruggeri M, Peccatori F, Azim Jr H, Colleoni M, et al.
N Engl J Med
. 2023 May;
388(18):1645-1656.
PMID: 37133584
Background: Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. Methods: We conducted a...
7.
Di Cosimo S, Ciniselli C, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, et al.
Front Oncol
. 2023 Feb;
12:1028825.
PMID: 36798690
Background: The absence of breast cancer cells in surgical specimens, , pathological complete response (pCR), is widely recognized as a favorable prognostic factor after neoadjuvant therapy. In contrast, the presence...
8.
Nuciforo P, Townend J, Piccart M, Fielding S, Gkolfi P, El-Abed S, et al.
Eur J Cancer
. 2023 Jan;
181:92-101.
PMID: 36641898
Background: Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on...
9.
Lambertini M, Ceppi M, Anderson R, Cameron D, Bruzzone M, Franzoi M, et al.
J Natl Compr Canc Netw
. 2023 Jan;
21(1):33-41.e16.
PMID: 36634607
Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid...
10.
Agostinetto E, Ameye L, Martel S, Aftimos P, Ponde N, Maurer C, et al.
NPJ Breast Cancer
. 2022 Jul;
8(1):87.
PMID: 35859079
The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated...